(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/127043 A1

(51) International Patent Classification:
A61K 31/437 (2006.01) *A61K 31/551* (2006.01)
A61K 31/519 (2006.01) *A61K 31/55* (2006.01)
A61K 31/506 (2006.01) *A61P 35/00* (2006.01)
A61K 31/427 (2006.01)

(21) International Application Number:
PCT/US2020/065408

(22) International Filing Date:
16 December 2020 (16.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/952,114 20 December 2019 (20.12.2019) US
63/009,758 14 April 2020 (14.04.2020) US

(71) Applicant: **RECURIUM IP HOLDINGS, LLC** [US/US]; 10835 Road to the Cure, Suite 205, San Diego, California 92121 (US).


(72) Inventors: **SAMATAR, Ahmed, Abdi**; 10835 Road to the Cure, Suite 205, San Diego, California 92121 (US). **LI, Jiali**; 10835 Road to the Cure, Suite 205, San Diego, California 92121 (US). **MA, Jianhui**; 10835 Road to the Cure, Suite 205, San Diego, California 92121 (US). **HUANG, Peter, Qinhua**; 10835 Road to the Cure, Suite 205, San Diego, California 92121 (US). **HEGDE, Sayee, Gajanan**; 10835 Road to the Cure, Suite 205, San Diego, California 92121 (US). **BUNKER, Kevin, Duane**; 10835 Road to the Cure, Suite 205, San Diego, California 92121 (US). **DONATE, Fernando**; 10835 Road to the Cure, Suite 205, San Diego, California 92121 (US).

(74) Agent: **MILLER, Kimberly, J.**; Knobbe, Martens, Olson & Bear, LLP , 2040 Main Street , 14th Floor, Irvine, California 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

(54) Title: COMBINATIONS

Figure 15



Combination study of Compound (A) with ribociclib in a MCF-7 xenograft tumor model

(57) **Abstract:** Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and another inhibitor (such as a CDK4/6 inhibitor, a selective aromatase inhibitor, a non-selective aromatase inhibitor, a mTOR inhibitor, a PI3K inhibitor, an ERK or a MEK inhibitor, AKT inhibitor, a BET inhibitor and an Aurora inhibitor), along with pharmaceutically acceptable salts of any of the foregoing.

WO 2021/127043 A1

[Continued on next page]

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*